ArticleIrish journal of medical science2026
Psychological impact of CDK4/6 inhibitors in HR+/HER2- advanced breast cancer: Insomnia, anxiety and menopausal symptoms assessed by the Nottingham health profile.
Article in Irish journal of medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesCDK4/6 inhibitors have significantly improved progression-free survival in hormone receptor-positive (HR+)/HER2-negative advanced breast cancer. However, their psychological impact, particularly on sleep quality, anxiety, and menopausal symptoms, remains underexplored.
objectivesThis study aimed to evaluate the prevalence of insomnia and its associations with psychological and menopausal symptoms in patients receiving CDK4/6 inhibitor therapy, using validated patient-reported outcome measures.
methodsA total of 63 women with stage IV HR+/HER2– breast cancer treated with either palbociclib or ribociclib were included. Sleep disturbances were assessed using the Pittsburgh Sleep Quality Index (PSQI), anxiety and depression via the Hospital Anxiety and Depression Scale (HADS), menopausal symptoms with the Menopause Rating Scale (MRS), and health-related quality of life using the Nottingham Health Profile (NHP).
resultsnsomnia (PSQI >5) was present in 54% of patients. Insomnia was significantly associated with younger age and presence of young children. While 41.2% and 39.7% of patients showed borderline or abnormal scores on HADS-A and HADS-D, respectively, no significant correlations were found between HADS scores and insomnia. Patients with insomnia had significantly higher MRS scores, indicating greater menopausal symptom burden. NHP analysis revealed no significant difference in total scores; however, domain-specific impairment in sleep was observed among patients with insomnia.
conclusionSleep disturbances are prevalent among HR+/HER2– advanced breast cancer patients receiving CDK4/6 inhibitors, often coexisting with menopausal symptoms and psychological distress. These findings highlight the need for routine screening and comprehensive supportive care strategies targeting sleep and mental health to optimize quality of life in this population.
Indexed as
Identifiers
41483094What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.